Content about Streptococcus pneumoniae

May 22, 2013
New pneumococcal vaccine as safe as previous version, study finds

A new vaccine against pneumococcal disease appears as safe as an older one, according to a new study.

PASADENA, Calif. — A new vaccine against pneumococcal disease appears as safe as an older one, according to a new study.

The study, conducted by Kaiser Permanente and published Wednesday in the journal Vaccine, compared the new 13-valent vaccine with the seven-valent one used before 2010. The Food and Drug Administration approved the newer vaccine, called PCV13, in 2010 after a series of trials. The valent number refers to the number of varieties of pneumococcal disease the vaccine prevents.

February 26, 2013
RxAlly, Shenandoah University pharmacy school collaborate in pneumococcal vaccination study

A Virginia-based pharmacy school will collaborate with an alliance of more than 22,000 pharmacies around the country to find ways to promote and increase pneumococcal vaccinations among elderly and high-risk people.

LEESBURG, Va. — A Virginia-based pharmacy school will collaborate with an alliance of more than 22,000 pharmacies around the country to find ways to promote and increase pneumococcal vaccinations among elderly and high-risk people.

January 28, 2013
FDA approves new use of Pfizer vaccine

The Food and Drug Administration has approved a new use for a pneumococcal vaccine made by Pfizer, the drug maker said.

NEW YORK — The Food and Drug Administration has approved a new use for a pneumococcal vaccine made by Pfizer, the drug maker said.

Pfizer announced the approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) for children and adolescents ages 6 years to 17 years for active immunization against the 13 Streptococcus pneumonia serotypes the vaccine covers. For this group, Prevnar 13 is administered as a one-time dose to patients who have never received it.

October 15, 2012
New recommendations out for pneumococcal vaccine in high-risk adults

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its recommendations for pneumococcal vaccine in high-risk adults.

ATLANTA — The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices has updated its recommendations for pneumococcal vaccine in high-risk adults.

ACIP now recommends the use of 13-valent pneumococcal conjugate vaccine (PCV13; Prevnar 13) for high-risk adults ages 19 years or older. The committee recommends that PCV13 should be administered to eligible adults in addition to the 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax 23), the vaccine currently recommended for these groups of adults.

January 3, 2012
FDA approves Prevnar 13 in older adults

The Food and Drug Administration has approved a Pfizer vaccine for Streptococcus pneumoniae in adults ages 50 years and older, the company said.

NEW YORK — The Food and Drug Administration has approved a Pfizer vaccine for Streptococcus pneumoniae in adults ages 50 years and older, the company said.

Pfizer announced the FDA approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) as a single-dose for adults.

March 17, 2010
Pfizer presents efficacy data of Prevenar 13 at conference

A phase-3 clinical trial found that a pneumococcal disease vaccine was well-tolerated and immunogenic in...

February 23, 2010
Prevnar 13 receives FDA approval

The Food and Drug Administration has approved a vaccine for preventing pneumococcal disease in children,...